• Phase 1 Trial for Prolanta in Advanced Ovarian Cancer Recruiting for Second Dose Group
  • Celsion to Initiate Phase 1/2 Trial of GEN-1 in Newly-diagnosed Ovarian Cancer Patients
  • Immix to Initiate Phase 1/2a Trial of IMX-110 in Ovarian, Other Solid Tumors
  • Study Aims to Identify Women with Ovarian Cancer Who May Benefit from Maintenance Treatment
  • Fluorescent Nanoparticles May Help to Spot Cancer Cells Surgeons Could Easily Miss
  • Aivita Launches Phase 2 Trial of Dendritic Cell Immunotherapy for Ovarian Cancer
  • Phase 1 Study Showing COTI-2 Safe in Potentially Treating Advanced Ovarian and Other Cancers
  • Tesaro’s Zejula for Recurrent Ovarian Cancer Now Available in Germany
  • Masitinib Counteracts Resistance to Ovarian Cancer Therapy in Cell Cultures
  • Mouse Study Reveals Potential Combination Therapy for Ovarian Cancer
  • First Recurrent Ovarian Cancer Patient Dosed with FATE-NK100 in APOLLO Trial
  • Higher Levels of Tumor T-cells Predict Better Survival Rates in Certain Ovarian Cancer Patients, Study Finds